Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2012

01-04-2012 | PRECLINICAL STUDIES

Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms—action of two new agents

Authors: Rajeev Kumar, Vikas Verma, Amit Sarswat, J. P. Maikhuri, Ashish Jain, Rajeev K. Jain, V. L. Sharma, Diwakar Dalela, Gopal Gupta

Published in: Investigational New Drugs | Issue 2/2012

Login to get access

Summary

The existing drugs for benign prostatic hyperplasia (BPH) are partially effective with undesirable side-effects; hence new agents acting by different mechanism(s) are required as supplements. Modulation of estrogen receptor signaling using selective estrogen receptor modulators (SERMs) offers an alternative approach for BPH management. Using human BPH-derived stromal cells and tissue explants in culture we evaluated two SERMs, DL-2-[4-(2-piperidinoethoxy)phenyl]-3-phenyl-2 H-1-benzopyran (BP) and Ormeloxifene (Orm) in comparison to Tamoxifen (Tam) and 4-hydroxytamoxifen (OHT). BP, OHT and Tam were more effective than Orm in reducing stromal cell proliferation of human BPH. BP was either equipotent or more effective than OHT and Tam in increasing estrogen receptor(ER)-ß, TGFß1, Fas and FasL, and in decreasing ER-α, AR, EGF-R and IGF-I expressions in BPH stromal cells. BP, Tam and Orm (1.0 mg/Kg) reduced rat prostate weights by almost same extent as Finasteride (Fin, 5.0 mg/Kg); however combination treatment (SERM+Fin) was more effective. BP was exceptionally efficient in reducing IGF-1 and cleaving PARP while combination treatments more effectively increased bax:bcl-2 ratio. Fin reduced acinar diameter and prostatic DHT level but increased testosterone, estradiol (E2) and E2/T+DHT ratio. SERMs, especially BP, reduced epithelial cell height drastically without significantly altering steroid hormone levels and E2/T+DHT ratio. Combination treatment reduced both acinar diameter and epithelial cell height with modest increase in E2, T and E2/T+DHT. The study reveals the potential of SERMs per se for BPH management, and more effectively in combination with a 5α-reductase inhibitor. BP appears promising for further evaluation as a drug candidate for BPH and prostate cancer.
Literature
1.
Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA (2009) Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 73:562–566PubMedCrossRef
2.
Greco KA, McVary KT (2008) The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 20(Suppl3):S33–S43PubMedCrossRef
3.
4.
5.
Weihua Z, Lathe R, Warner M, Gustafsson JA (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A 99:13589–13594PubMedCrossRef
6.
Lee DK, Chang C (2003) Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 88:4043–4054PubMedCrossRef
7.
Harkonen PL, Makela SI (2004) Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 92:297–305PubMedCrossRef
8.
Johnson JJ, Syed DN, Suh Y, Heren CR, Saleem M, Siddiqui IA, Mukhtar H (2010) Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res (Phila) 3:1112–1123CrossRef
9.
Glienke W, Dolgova Y, Muller I, Grosch S, Binder J, Geisslinger G, Jonas D (2004) Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia. World J Urol 22:452–456PubMedCrossRef
10.
Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC (2006) Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol 100:24–33PubMedCrossRef
11.
12.
Santeufemia DA, Capobianco G, Dessole S, Tolu F, Fadda GM, Di Meglio G, Farris A (2009) Tamoxifen induced severe hypertriglyceridemia in a male patient with breast carcinoma. Breast J 15:675–676PubMedCrossRef
13.
Chen HY, Dykstra KD, Birzin ET, Frisch K, Chan W, Yang YT, Mosley RT, DiNinno F, Rohrer SP, Schaeffer JM, Hammond ML (2004) Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity. Bioorg Med Chem Lett 14:1417–1421PubMedCrossRef
14.
Brössner C, Petritsch K, Fink K, Auprich M, Madersbacher S, Adlercreutz H, Rehak P, Petritsch P (2004) Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology 64:707–711PubMedCrossRef
15.
Hong SJ, Kim SI, Kwon SM, Lee JR, Chung BC, Yonsei (2002) Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Med J 43:236–241
16.
Griffiths K, Denis L, Turkes A, Morton MS, Baillieres (1998) Phytoestrogens and diseases of the prostate gland. Clin Endocrinol Metab 12:625–647
17.
Denis L, Morton MS, Griffiths K (1999) Diet and its preventive role in prostatic disease. Eur Urol 35:377–387PubMedCrossRef
18.
Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI, Paniagua R (2001) Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 168:447–454PubMedCrossRef
19.
McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP (2007) Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148:566–574PubMedCrossRef
20.
Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA, Chen K, Wang Y, Durst GL, Barr RJ, Montrose-Rafizadeh C, Osborne HE, Amos RM, Guo S, Boodhoo A, Krishnan V (2006) Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 49:6155–6157PubMedCrossRef
21.
Richardson TI, Norman BH, Lugar CW, Jones SA, Wang Y, Durbin JD, Krishnan V, Dodge JA (2007) Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold. Bioorg Med Chem Lett 17:3570–3574PubMedCrossRef
22.
Saeed A, Sharma AP, Durani N, Jain R, Durani S, Kapil RS (1990) Structure-activity relationship of antiestrogens. Studies on 2, 3-diaryl-1-benzopyrans. J Med Chem 33:3210–3216PubMedCrossRef
23.
Sharma AP, Saeed A, Durani S, Kapil RS (1990) Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2, 3-diaryl-2 H–1-benzopyrans. J Med Chem 33:3216–3222PubMedCrossRef
24.
Sharma AP, Saeed A, Durani S, Kapil RS (1990) Structure-activity relationship of antiestrogens. Phenolic analogues of 2, 3-diaryl-2 H–1-benzopyrans. J Med Chem 33:3222–3229PubMedCrossRef
25.
Singh MM (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 21:302–347PubMedCrossRef
26.
Padayatty SJ, Marcelli M, Shao TC, Cunningham GR (1997) Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 82:1434–1439PubMedCrossRef
27.
Le Tortorec A, Satie AP, Denis H, Rioux-Leclercq N, Havard L, Ruffault A, Jegou B, Dejucq-Rainsford N (2008) Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. Retrovirology 5:119PubMedCrossRef
28.
Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT (2004) Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145(12):5420–5428PubMedCrossRef
29.
Fitts JM, Klein RM, Powers CA (2004) Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J Androl 25(4):523–534PubMed
30.
Weihua Z, Lathe R, Warner M, Gustafsson JA (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 99:13589–13594PubMedCrossRef
31.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930PubMedCrossRef
32.
Dhar JD, Dwivedi A, Srivastava A, Setty BS (1994) Structure activity relationship of some 2, 3-diaryl-2 H–1-benzopyrans to their anti-implantation, estrogenic and antiestrogenic activities in rat. Contraception 49:609–616PubMedCrossRef
33.
Trukhacheva E, Lin Z, Reierstad S, Cheng YH, Milad M, Bulun SE (2009) Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis. J Clin Endocrinol Metab 94(2):615–622PubMedCrossRef
34.
Steiner MS, Pound CR (2003) Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2:24–31PubMed
35.
Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D, Steiner M (2006) Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176:965–970PubMedCrossRef
36.
Mobbs BG, Johnson IE, Connolly JG, Thompson J (1983) Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J Steroid Biochem 19:1279–1290PubMedCrossRef
37.
Blanchere M, Berthaut I, Portois MC, Mestayer C, Mowszowicz I (1998) Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J Steroid Biochem Mol Biol 66:319–326PubMedCrossRef
38.
McPherson SJ, Ellem SJ, Risbridger GP (2008) Estrogen-regulated development and differentiation of the prostate. Differentiation 76:660–670PubMedCrossRef
39.
Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. Faseb J 22:1512–1520PubMedCrossRef
40.
Montanaro D, Maggiolini M, Recchia AG, Sirianni R, Aquila S, Barzon L, Fallo F, Andò S, Pezzi V (2005) Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation. J Mol Endocrinol 35:245–256PubMedCrossRef
41.
Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, Thelen P (2007) The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6:2626–2633PubMedCrossRef
42.
Brolin J, Skoog L, Ekman P (1992) Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20:281–295PubMedCrossRef
43.
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167–1177PubMedCrossRef
44.
Ho CK, Nanda J, Chapman KE, Habib FK (2008) Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 197:483–491PubMedCrossRef
45.
Soulitzis N, Karyotis I, Delakas D, Spandidos DA (2006) Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 29:305–314PubMed
46.
Rana S, Sen R, Kalra R, Arora B, Sharma P, Gahlawat S (2006) Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma. Indian J Pathol Microbiol 49:495–499PubMed
47.
de Miguel MP, Royuela M, Bethencourt FR, Santamaria L, Fraile B, Paniagua R (2000) Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine 12:535–538PubMedCrossRef
48.
Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T (2004) Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 25:237–240PubMedCrossRef
49.
Fleisch MC, Maxwell CA, Barcellos-Hoff MH (2006) The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer 13:379–400PubMedCrossRef
50.
Symes JC, Kurin M, Fleshner NE, Medin JA (2008) Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther 7:3018–3028PubMedCrossRef
51.
King KJ, Nicholson HD, Assinder SJ (2005) Effect of increasing ratio of estrogen:androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. Prostate 66:105–114CrossRef
52.
Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H (2000) Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42:45–55PubMedCrossRef
53.
Banerjee PP, Banerjee S, Lai JM, Strandberg JD, Zirkin BR, Brown TR (1998) Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. Biol Reprod 59:1163–1170PubMedCrossRef
54.
Habenicht UF, Tunn UW, Senge T, Schröder FH, Schweikert HU, Bartsch G, El Etreby MF (1993) Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol 44:557–563PubMedCrossRef
55.
56.
Nomura H, Kawashima H, Masaki S, Hosono TY, Matsumura K, Tamada S, Tanaka T, Nakatani T (2009) Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer Prostatic Dis 12:375–381PubMedCrossRef
57.
Steiner MS, Raghow S (2003) Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol 21:31–36PubMed
Metadata
Title
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms—action of two new agents
Authors
Rajeev Kumar
Vikas Verma
Amit Sarswat
J. P. Maikhuri
Ashish Jain
Rajeev K. Jain
V. L. Sharma
Diwakar Dalela
Gopal Gupta
Publication date
01-04-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9620-2

Other articles of this Issue 2/2012

Investigational New Drugs 2/2012 Go to the issue

SHORT REPORT

Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL

PRECLINICAL STUDIES

Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway

SHORT REPORT

The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL

PRECLINICAL STUDIES

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents

PHASE II STUDIES

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

PRECLINICAL STUDIES

The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits